Skip to content

Obulytix

Active
Private limited companyfounded 20233 yrs activeSuzanne Tassierstraat 1, 9052 Gent, BelgiumKBO/BCE: BE 0803.351.624
Summary

The computed 12-month bankruptcy probability of Obulytix is 1.9% (moderate). The 2024 annual accounts show equity of €3.8m and a net result of -€1.1m. Its solvency ranks better than 80% of 51 sector peers (fiscal year 2024). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.

Checked score

Score 2024
Axes
Profitability0
Solvency100
Growth-
Track record79
Bankruptcy probability, 12 months
1.9% Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €220,000 at 30 days acceptable
Liquidity ample (current ratio 9.0; short-term debt: 6.7% and cash: 29.7% of total assets), and 25.1% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Four signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 3 years 0 10 y
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024
Solvency, return and age of the figures
Solvency
74.9%
Return on assets
-21.2%
Age of the figures
21 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 02-07-2025, 29 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2024
29 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its 2024 accounts 29 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 29 June 2023, Obulytix was incorporated as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2024.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2024

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2024, abbreviated schema

Equity
€3.8m
Total assets
€5.1m
Net result
-€1.1m
Working capital
€2.7m

Turnover and EBIT margin not published: the abbreviated schema does not require them.

Balance-sheet composition
Assets €5.1m
Fixed assets €2.0m
Current assets €3.1m
Equity and liabilities €5.1m
Equity €3.8m
Debt €1.3m
Debt finances 25.1% of the balance-sheet total.
Key figures and ratios
2024 value
EBITDA
-€843,266
Cash flow
-€827,140
Current ratio
9.00
Debt to equity
0.34
ROE
-28.3%
ROA
-21.2%
Interest coverage
-712.21
Debt ≤ 1 year
€342,198
Staff costs
€252,666

Peer companies

Historical observation

Of the 3,227 companies that looked in July 2024 the way this one looks now, 2.9% went bankrupt within 24 months and 87% are still going.

  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more
2.9% went bankrupt
8.6% stopped otherwise
87% still going

A further 1.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 1.9% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.7%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 3,227 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2024 · 40 lines
Balance sheet Code2024
Assets
Total assets20/58€5.1m
Formation expenses20€51,052
Fixed assets21/28€2.0m
Intangible fixed assets21€1.8m
Tangible fixed assets22/27€221,644
Plant, machinery and equipment23€211,110
Furniture and vehicles24€10,534
Current assets29/58€3.1m
Amounts receivable after more than one year29€981,754
Other amounts receivable291€981,754
Amounts receivable within one year40/41€580,489
Other amounts receivable41€580,489
Cash at bank and in hand54/58€1.5m
Deferred charges and accrued income490/1€2,933
Equity and liabilities
Total equity and liabilities10/49€5.1m
Equity10/15€3.8m
Contributions10/11€4.7m
Profit (loss) carried forward14-€1.1m
Investment grants15€233,144
Amounts payable17/49€1.3m
Amounts payable within one year42/48€342,198
Trade debts44€315,167
Suppliers440/4€315,167
Taxes, remuneration and social security45€27,031
Remuneration and social security454/9€27,031
Accrued charges and deferred income492/3€938,798
Income statement Code2024
Remuneration, social security and pensions62€252,666
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€254,014
Other operating charges640/8€150
Gross operating margin9900-€590,450
Operating profit (loss)9901-€1.1m
Financial income75/76B€17,311
Recurring financial income75€17,311
Financial charges65/66B€1,184
Recurring financial charges65€1,184
Profit (loss) for the period before taxes9903-€1.1m
Profit (loss) for the period9904-€1.1m
Profit (loss) for the period to be appropriated9905-€1.1m
Appropriation of the result
Profit (loss) to be appropriated9906-€1.1m
Social balance
Average headcount (FTE)90872.6

The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2024
Remuneration, social security and pensions62€252,666
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€254,014
Other operating charges640/8€150
Gross operating margin9900-€590,450
Operating profit (loss)9901-€1.1m
Financial income75/76B€17,311
Recurring financial income75€17,311
Financial charges65/66B€1,184
Recurring financial charges65€1,184
Profit (loss) for the period before taxes9903-€1.1m
Profit (loss) for the period9904-€1.1m
Profit (loss) for the period to be appropriated9905-€1.1m
Line2024
Assets
Total assets20/58€5.1m
Formation expenses20€51,052
Fixed assets21/28€2.0m
Intangible fixed assets21€1.8m
Tangible fixed assets22/27€221,644
Plant, machinery and equipment23€211,110
Furniture and vehicles24€10,534
Current assets29/58€3.1m
Amounts receivable after more than one year29€981,754
Other amounts receivable291€981,754
Amounts receivable within one year40/41€580,489
Other amounts receivable41€580,489
Cash at bank and in hand54/58€1.5m
Deferred charges and accrued income490/1€2,933
Equity and liabilities
Total equity and liabilities10/49€5.1m
Equity10/15€3.8m
Contributions10/11€4.7m
Profit (loss) carried forward14-€1.1m
Investment grants15€233,144
Amounts payable17/49€1.3m
Amounts payable within one year42/48€342,198
Trade debts44€315,167
Suppliers440/4€315,167
Taxes, remuneration and social security45€27,031
Remuneration and social security454/9€27,031
Accrued charges and deferred income492/3€938,798
Line2024
Profit (loss) for the period9904-€1.1m
+ Depreciation and write-downs630€254,014
Operating cash flow (approximation)-€827,140

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2025
02-07
NBB filing Annual accounts filed
fiscal year 2024 · abbreviated schema
NBB filing
0 of 7 acts read
About the unread acts

We know of 7 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
7 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2023
seat establishment The establishment unit on the map
Ground area
6,161 m²
Building footprint
1,560 m²
Parcel 44082B0667/00A000, Flanders. Linked by address, not a title deed.
19 companies at this address See who is registered here
1 establishment unit
ComBioNX
Suzanne Tassierstraat 1, 9052 GentManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20232.347.302.010
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44082B0667/00A000 Flanders 6,161 m² 1 · 1,560 m² -
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Structure & network

Owners and holdings

1 owner

Owners 1

Holdings 0

No holding stated in the accounts, acts or LEI register we read.

According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

No current directors or connected companies found in the register.

Public money · subsidies and aid

Flemish government

2024 to 2025 · 8 entries · 1,864,499 EUR awarded · 880,495 EUR paid
Year Entries awardedpaid
2025 5 2,250 EUR473,000 EUR
2024 3 1,862,249 EUR407,495 EUR
Schemes
3 entries · 1,528,358 EUR · 814,000 EUR paid · Fonds voor Innoveren en Ondernemen
3 entries · 333,396 EUR · 66,000 EUR paid · Fonds voor Innoveren en Ondernemen
2 entries · 2,745 EUR · 495 EUR paid · Fonds voor Innoveren en Ondernemen

European Union, budget

2025 · 1 entry · 1,485,619 EUR in total
Year Entries awarded
2025 1 1,485,619 EUR
Projects
END2AMR - EUROPEAN NOVEL DRUG RESEARCH TO ADDRESS MICROBIAL INFECTIONS AND DRUG RESISTANCE
Decentralised Agencies, Joint Undertakings, EU institutions · 01-01-2026 to 31-12-2030 · 1,485,619 EUR

European research

1 project · 1,485,615 EUR EU contribution
Programmes
1 entry · 1,485,615 EUR
Projects
European Novel Drug research to Address Microbial infections and drug Resistance
Horizon Europe · participant · 01-01-2026 to 31-12-2030 · 1,485,615 EUR · END2AMR

Similar companies · same sector, comparable size

Of 148 companies in sector 21201 we hold annual accounts for 118. 64 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded29-06-2023
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
72109Other research and development on natural sciences
E-invoicing
Reachable via Peppol
Peppol ID 0208:0803351624
Also 9925:BE0803351624
Registered 28-08-2025

Register as of 28 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.